29

October

2015

MGB Biopharma to attend BIO-Europe 2015

Glasgow, Scotland, 29 October 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

10

September

2015

MGB Biopharma Wins Scottish Business Award

Glasgow, Scotland, 10th September 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

21

July

2015

MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections

Glasgow, Scotland, 21st July 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem...

Read More

2

June

2015

MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-positive hospital-acquired Infections

Glasgow, Scotland, 2nd June 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem...

Read More

15

May

2015

MGB Biopharma Fully Supports the Latest Report from Jim O’Neill’s Review on Antimicrobial Resistance

Glasgow, Scotland, 15th May 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of  anti-infectives, endorses the latest report from Jim...

Read More

24

March

2015

MGB Biopharma to Present at the Superbugs & Superdrugs Conference in London on 26th March

Glasgow, Scotland, 24th March 2015 – MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that Dr Dawn Firmin, Head of Project...

Read More

12

January

2015

MGB Biopharma continues to progress its truly novel anti-infectives platform to tackle antibiotic resistance in 2014

Highlights In September 2014, MGB Biopharma secured £4M ($6.4M) from leading Scottish investors and Innovate UK for further clinical development of lead antibiotic MGB-BP-3...

Read More

8

December

2014

MGB Biopharma Announces Collaborations with Almac Group Ltd and Encap Drug Delivery to Manufacture Lead Antibiotic MGB-BP-3

Glasgow, Scotland, 08 December 2014 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, is pleased to announce that it...

Read More

1

December

2014

MGB Biopharma Nominated and Shortlisted for Scottish Enterprise Life Sciences Award

Glasgow, Scotland, 1 December 2014 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has been...

Read More

26

November

2014

MGB Biopharma in the News – European Pharmaceutical Contractor

Immediate Action: Drug-Resistant Bacteria, article written by Dr Dawn Firmin, Head of Project Management at MGB Biopharma Limited. This article was published in the December 2014...

Read More